Surgery Partners (NASDAQ:SGRY) Sets New 52-Week Low Following Weak Earnings

Surgery Partners, Inc. (NASDAQ:SGRY) shares reached a new 52-week low on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $12.25 and last traded at $12.4250, with a volume of 1596453 shares trading hands. The stock had previously closed at $15.88.

The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). The business had revenue of $885.00 million during the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. Surgery Partners’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.44 earnings per share.

Surgery Partners declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 9.7% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Announced a share repurchase program, which can support the stock by returning capital and offsetting dilution. Share repurchase program
• Positive Sentiment: Revenue beat: Q4 revenue was $885.0M vs. ~$866.5M consensus, and revenue was up ~2.4% year‑over‑year, showing underlying demand resilience in the business. Q4 revenue beat
• Neutral Sentiment: Q4 earnings call transcript published — useful for detail on margins, volumes, and management commentary for modeling but does not itself move fundamentals. Earnings call transcript
• Negative Sentiment: Earnings miss: Q4 EPS was $0.12 vs. consensus ~$0.31 (and vs. $0.44 a year ago), a substantial shortfall that hit investor confidence. Earnings miss
• Negative Sentiment: Weaker FY‑2026 guidance: management set revenue roughly in a $3.4B–$3.5B range vs. consensus near $3.5B and left EPS guidance unclear/limited, signaling slower growth or margin pressures. That guidance was a primary cause of the selloff. Guidance and outlook
• Negative Sentiment: Analyst reaction: Barclays cut its price target to $14 and moved to an “equal weight” stance, reducing upside expectations and likely keeping additional selling pressure on the stock. Barclays price target cut
• Negative Sentiment: Market reaction: multiple reports show the stock fell sharply on the earnings/guidance news (heavy volume), reflecting investor disappointment and increased near‑term downside risk. Market reaction

Analyst Ratings Changes

Several equities analysts recently issued reports on SGRY shares. Jefferies Financial Group set a $30.00 target price on shares of Surgery Partners in a research note on Tuesday. Royal Bank Of Canada cut their price objective on shares of Surgery Partners from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. lowered their target price on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating on the stock in a research note on Monday, November 24th. UBS Group dropped their target price on Surgery Partners from $34.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Surgery Partners presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Institutional Trading of Surgery Partners

A number of institutional investors and hedge funds have recently modified their holdings of SGRY. Alpine Global Management LLC purchased a new position in Surgery Partners in the 4th quarter valued at about $175,000. Empowered Funds LLC raised its holdings in shares of Surgery Partners by 1,340.9% during the fourth quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock valued at $2,494,000 after acquiring an additional 150,216 shares during the last quarter. One68 Global Capital LLC purchased a new position in shares of Surgery Partners in the fourth quarter valued at approximately $371,000. Man Group plc acquired a new stake in shares of Surgery Partners in the fourth quarter worth approximately $5,080,000. Finally, Inspire Investing LLC increased its position in shares of Surgery Partners by 45.4% during the fourth quarter. Inspire Investing LLC now owns 30,073 shares of the company’s stock worth $465,000 after purchasing an additional 9,384 shares in the last quarter.

Surgery Partners Price Performance

The company has a 50-day moving average of $15.32 and a 200 day moving average of $18.27. The company has a quick ratio of 1.72, a current ratio of 1.88 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $1.80 billion, a PE ratio of -22.45 and a beta of 1.95.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.